Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
AstraZeneca plc (NYSE: AZN) shares declined 1.19 percent to close at $50.63 a share Tuesday. The stock traded between $50.57 and $51.11 on volume 1.17 million shares traded. The company has agreed to acquire cancer drug developer Spirogen for up to $440.0 million. Shares of AstraZeneca have gained approximately 7.0 percent year-to-date.
Get more information on AstraZeneca free access to the in-depth equity report at:
Domino's Pizza, Inc. (NYSE: DPZ) shares declined 5.74 percent to close at $64.90 a share Tuesday. The stock traded between $64.89 and $67.34 on volume of 2.37 million shares traded. The company reported earnings were $30.6 million, or $0.53 per share, for the third quarter of 2013, which fell short of analysts’ expectations of $0.52 per share, according to FactSet. Shares of Domino's Pizza have gained approximately 8.0 percent year-to-date.
Get more information on Domino's Pizza and free access to the in-depth equity report at:
DexCom, Inc. (NASDAQ: DXCM) shares gained 1.48 percent to close at $29.47 a share Tuesday. The stock traded between $29.15 and $30.47 on volume of 1.03 million shares traded. Benchmark Co. analyst Jan Wald has recently initiated coverage on the company with a buy rating and a price target of $37.00. Shares of DexCom have gained approximately 115.0 percent year-to-date.
Get more information on DexCom and free access to the in-depth equity report at:
Johnson & Johnson (NYSE: JNJ) shares gained 0.14 percent to close at $89.93 a share Tuesday. The stock traded between $89.93 and $91.46 on volume of 11.02 million shares traded. The company reported sales of $17.6 billion for the third quarter of 2013, an increase of 3.1 percent when compared to a year ago. Shares of Johnson & Johnson have gained approximately 28.0 percent year-to-date.
Get more information on Johnson & Johnson and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...